Conclusion: These findings present G6PD, Cyclin E1 and MMP9, which contribute to ccRCC progression, as novel biomarkers and potential therapeutic targets for ccRCC treatment. This evidence concerns the gene G6PD and nonpapillary renal cell carcinoma.